Open access
Open access
Powered by Google Translator Translator

Oncology – Gastrointestinal

RCT | Superior PFS with avelumab vs. chemotherapy in second-line treatment for mCRC with microsatellite instability

11 Aug, 2023 | 15:25h | UTC

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial – JAMA Oncology

See also: Visual Abstract

Commentary: Avelumab Outperforms Standard Second-Line Therapy in dMMR/MSI Metastatic CRC – Cancer Therapy Advisor

 


Cohort Study | Moderate to heavy drinking linked to increased risk of early-onset colorectal cancer

9 Aug, 2023 | 15:27h | UTC

Sex and Tumor-Site Differences in the Association of Alcohol Intake With the Risk of Early-Onset Colorectal Cancer – Journal of Clinical Oncology

Commentary: Association of Alcohol Intake With Risk of Early-Onset Colorectal Cancer – The ASCO Post

 

Commentary on Twitter

 


Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey

8 Aug, 2023 | 13:22h | UTC

Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey – HPB

 

Commentary on Twitter

 


RCT | Zolbetuximab plus CAPOX as potential first-line treatment for CLDN18.2+, HER2- advanced gastric adenocarcinoma

7 Aug, 2023 | 14:38h | UTC

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial – Nature Medicine

 

Commentary on Twitter

 


ACP Guidance | Asymptomatic CRC screening advised from age 50 with fecal occult blood test every 2 years or colonoscopy every 10 years

3 Aug, 2023 | 13:48h | UTC

Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians – Annals of Internal Medicine

News Release: ACP issues updated guidance for colorectal cancer screening of asymptomatic adults – American College of Physicians

Commentary: Start screening for colorectal cancer at age 50 years, ACP suggests – ACP Internist

Summary for Patients: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults – Annals of Internal Medicine

 


RCT | Camrelizumab-rivoceranib outperforms sorafenib as first-line therapy for unresectable HCC

2 Aug, 2023 | 13:53h | UTC

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Nonrandomized Controlled Trial | Long-term survival of 80% in selected colorectal cancer patients post liver transplant

1 Aug, 2023 | 14:20h | UTC

Long-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant: A Nonrandomized Controlled Trial – JAMA Surgery (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Efficacy of different treatment regimens in unresectable colorectal cancer liver metastases

14 Jul, 2023 | 12:42h | UTC

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | FOLFOXIRI-Bevacizumab shows promise as first-line treatment in unresectable colorectal cancer metastases

5 Jul, 2023 | 01:02h | UTC

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group – The Lancet Oncology (link to abstract – $ for full-tetxt)

 


Consensus Paper | Colorectal neuroendocrine tumors

30 Jun, 2023 | 14:45h | UTC

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours – Journal of Neuroendocrinology

 


SR | Supportive care interventions for managing gastrointestinal symptoms following treatment for colorectal cancer

22 Jun, 2023 | 14:49h | UTC

Supportive care interventions for managing gastrointestinal symptoms following treatment for colorectal cancer: a systematic review – Journal of Cancer Survivorship

 


RCT | Fruquintinib extends median survival to 7.4 months vs. 4.8 months with placebo in refractory metastatic colorectal cancer

19 Jun, 2023 | 14:02h | UTC

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter questioning the control group (thread – click for more)

 


Cohort Study | Overweight or obesity in early and middle adulthood linked to higher gastrointestinal cancer risk

5 Jun, 2023 | 13:34h | UTC

Analysis of Body Mass Index in Early and Middle Adulthood and Estimated Risk of Gastrointestinal Cancer – JAMA Network Open

Editorial: Obesity and Gastrointestinal Cancer: A Life Course Perspective – JAMA Network Open

Commentary: Association Between Overweight/Obesity and Risk of Gastrointestinal Cancer – The ASCO Post

 


AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

30 May, 2023 | 11:51h | UTC

AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma – Hepatology

 


M-A | Prehabilitation may enhance functional capacity in pre- and postoperative colorectal cancer patients

30 May, 2023 | 11:50h | UTC

Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery – Cochrane Library

Summary: Preparing a patient with bowel cancer for surgery with multiple interventions – Cochrane Library

 


Review | Cholangiocarcinoma — novel biological insights and therapeutic strategies

22 May, 2023 | 13:38h | UTC

Cholangiocarcinoma — novel biological insights and therapeutic strategies – Nature Reviews Clinical Oncology

 

Commentary on Twitter

 


Review | Hereditary colorectal, gastric, and pancreatic cancer

18 May, 2023 | 13:43h | UTC

Hereditary colorectal, gastric, and pancreatic cancer: comprehensive review – BJS Open

 

Commentary on Twitter

 


Current perioperative care in pancreatoduodenectomy: a step-by-step surgical roadmap from first visit to discharge

16 May, 2023 | 14:52h | UTC

Current Perioperative Care in Pancreatoduodenectomy: A Step-by-Step Surgical Roadmap from First Visit to Discharge – Cancers

 

Commentary on Twitter

 


An update on the role of immunohistochemistry in the evaluation of pancreatic/liver/gastrointestinal luminal tract disorders

15 May, 2023 | 13:02h | UTC

An Update on the Role of Immunohistochemistry in the Evaluation of Pancreatic/Liver/Gastrointestinal Luminal Tract Disorders – Archives of Pathology & Laboratory Medicine

 


2023 Rectal cancer lexicon update | Revised consensus on terminology and staging

15 May, 2023 | 12:50h | UTC

Rectal cancer lexicon 2023 revised and updated consensus statement from the Society of Abdominal Radiology Colorectal and Anal Cancer Disease-Focused Panel – Abdominal Radiology

 


EASL-ILCA Clinical practice guidelines on the management of intrahepatic cholangiocarcinoma

9 May, 2023 | 14:47h | UTC

EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma – Journal of Hepatology

 

Commentary on Twitter

 


RCT | Tislelizumab plus chemotherapy vs placebo plus chemotherapy for advanced esophageal squamous cell carcinoma

8 May, 2023 | 13:04h | UTC

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Adding Bevacizumab to trifluridine–tipiracil enhances overall survival in refractory metastatic colorectal cancer

5 May, 2023 | 15:13h | UTC

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer

2 May, 2023 | 13:36h | UTC

Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial – JAMA Surgery (free for a limited period)

Invited Commentary: Heated Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer–Restarting the Fire – JAMA Surgery (free for a limited period)

 

Commentary on Twitter

 


Review | Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma

28 Apr, 2023 | 13:03h | UTC

Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma – CA: A Cancer Journal for Clinicians

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.